Supreme Court Intervenes in Delayed Kerala Case on Affordable Access to Life-Saving Cancer Drugs
The Supreme Court took suo motu cognisance of delays in the Kerala High Court regarding a petition filed in 2022 by a breast cancer patient seeking affordable access to the patented drug Ribociclib. Despite being listed 57 times, the case remained undecided, and the petitioner died during the pendency. The Kerala High Court continued the case in public interest, and the Supreme Court issued notices to the Centre and Kerala, urging expeditious disposal and considering a pan-India approach to address pricing and accessibility of life-saving medicines under Article 21.
First-hand measurement across 10 sources
We measured how 10 outlets covered this story. Coverage leans balanced overall (Left 44%, Centre 54%, Right 2%). Overall sentiment is neutral (42/100). Lens Score 39/100 — moderate-to-low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- hindustantimes— balanced framing, neutral sentiment
- indianexpress— balanced framing, neutral sentiment
- timesnow— balanced framing, neutral sentiment
- thetribune— balanced framing, neutral sentiment
- thehindu— balanced framing, neutral sentiment
- thetribune— balanced framing, neutral sentiment
- ndtv— left-leaning framing, neutral sentiment
- news18— balanced framing, neutral sentiment
AI Analysis
The article group presents perspectives from the judiciary, patient advocates, and government representatives without favoring any political party. It highlights judicial concerns over delays, patient rights to affordable medicines, and government responses, reflecting a focus on legal and public health issues rather than partisan viewpoints. The coverage includes official statements and civil society appeals, maintaining a balanced representation of stakeholders.
The overall tone is serious and concerned, emphasizing judicial frustration over procedural delays and the tragic death of the petitioner. While the coverage acknowledges government efforts to provide medicines, it underscores systemic challenges in drug affordability and access. The sentiment is predominantly neutral to critical regarding delays, with a constructive outlook on potential judicial remedies and broader policy implications.